Antibody-mediated Rejection Market Forecast 2034: Clinical Trials, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, CSL Behring, Bristol

(Albany, USA) DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody-mediated Rejection, historical and forecasted epidemiology as well as the Antibody-mediated Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Antibody-mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-mediated Rejection Market Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Antibody-mediated Rejection Market Report:
• The Antibody-mediated Rejection market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2024, Human Immunology Biosciences (HI-Bio™), a biotech firm in the clinical stage, specializing in tailored treatments for individuals grappling with severe immune-mediated disorders (IMDs), has revealed that the U.S. Food and Drug Administration (FDA) has conferred Orphan Drug Designation (ODD) upon felzartamab. This designation is specifically for addressing antibody-mediated rejection (AMR) in recipients of kidney transplants.
• The incidence of Antibody-mediated Rejection in kidney transplants was highest in the United States. According to DelveInsight's predictions, the number of kidney transplants performed nationwide in 2019 was 1,887; this number is projected to rise by 2034
• France had the most antibody-mediated rejection (AMR) instances among the European nations in 2019 with 459 cases, followed by Spain with 419 cases. Germany, on the other side, had the lowest number in 2019, with 259 cases
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• The Antibody-mediated Rejection epidemiology based on gender analyzed that both males and females are affected equally by Antibody-mediated Rejection
• The Antibody-mediated Rejection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody-mediated Rejection pipeline products will significantly revolutionize the Antibody-mediated Rejection market dynamics.

Antibody-mediated Rejection Overview
Antibody-mediated rejection (AMR) is a significant complication in organ transplantation, primarily involving the immune system's response against the transplanted organ. It occurs when the recipient's immune system produces antibodies that recognize the donor organ as foreign, leading to organ damage and dysfunction. These antibodies target antigens on the donor's vascular endothelium, triggering a cascade of immune responses, including complement activation and recruitment of inflammatory cells.
Antibody-mediated Rejection is characterized by specific histological features such as capillary inflammation, complement component C4d deposition, and the presence of donor-specific antibodies (DSAs) in the recipient's bloodstream. This type of rejection is more challenging to treat than cellular rejection due to its complex pathophysiology. Antibody-mediated Rejection Management typically involves plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppressive therapies to reduce antibody production and mitigate organ damage. Early diagnosis and treatment are crucial to improve graft survival and patient outcomes. Advances in diagnostics and therapeutics continue to evolve in managing Antibody-mediated Rejection effectively.

Get a Free sample for the Antibody-mediated Rejection Market Report:
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Antibody-mediated Rejection Epidemiology Segmentation:
The Antibody-mediated Rejection market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Antibody-mediated Rejection
• Prevalent Cases of Antibody-mediated Rejection by severity
• Gender-specific Prevalence of Antibody-mediated Rejection
• Diagnosed Cases of Episodic and Chronic Antibody-mediated Rejection

Download the report to understand which factors are driving Antibody-mediated Rejection epidemiology trends @ Antibody-mediated Rejection Epidemiology Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Antibody-mediated Rejection Therapies and Key Companies
• Clazakizumab: CSL Behring
• Imlifidase: Hansa Biopharma
• VIB4920 (HZN-4920): Horizon Therapeutics
• Felzartamab: Farsad Eskandary
• Physiologic saline solution: CSL Behring
• Belatacept: Bristol-Myers Squibb
• Daratumumab: Janssen, LP
• BIVV020 (SAR445088): Sanofi
• Nulojix (Belatacept): Bristol-Myers Squibb
• Eculizumab: Alexion

Discover more about therapies set to grab major Antibody-mediated Rejection market share @ Antibody-mediated Rejection Treatment Market
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-mediated Rejection Market Drivers
• Emerging Therapy
• Development of Personalized Therapy
• Targeting of Novel Pathways
• Increased Rate of Organ Donation
• Development of Gene therapy

Antibody-mediated Rejection Market Barriers
• Challenges in Designing Clinical Trials
• Need for Evidence-based Treatment Guidelines
• High Clinical Burden

Scope of the Antibody-mediated Rejection Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• Antibody-mediated Rejection Therapeutic Assessment: Antibody-mediated Rejection current marketed and Antibody-mediated Rejection emerging therapies
• Antibody-mediated Rejection Market Dynamics: Antibody-mediated Rejection market drivers and Antibody-mediated Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Antibody-mediated Rejection Unmet Needs, KOL's views, Analyst's views, Antibody-mediated Rejection Market Access and Reimbursement

To know more about Antibody-mediated Rejection companies working in the treatment market, visit @ Antibody-mediated Rejection Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Antibody-mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-mediated Rejection
3. SWOT analysis of Antibody-mediated Rejection
4. Antibody-mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-mediated Rejection Market Overview at a Glance
6. Antibody-mediated Rejection Disease Background and Overview
7. Antibody-mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-mediated Rejection
9. Antibody-mediated Rejection Current Treatment and Medical Practices
10. Antibody-mediated Rejection Unmet Needs
11. Antibody-mediated Rejection Emerging Therapies
12. Antibody-mediated Rejection Market Outlook
13. Country-Wise Antibody-mediated Rejection Market Analysis (2020-2034)
14. Antibody-mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-mediated Rejection Market Drivers
16. Antibody-mediated Rejection Market Barriers
17. Antibody-mediated Rejection Appendix
18. Antibody-mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Anti-gbm Market: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights
• Autosomal Recessive Congenital Ichthyosis Market Size: https://www.delveinsight.com/report-store/autosomal-recessive-congenital-ichthyosis-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Familial Chylomicronemia Syndrome Market: https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
• Lhon Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Rituximab Biosimilars Insight: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight
• Severe Hypertriglyceridemia Market: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
• Waiha Market: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/blog/adult-onset-stills-disease-treatment-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Heavy Metal Poisoning Market: https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Prosthetic Joint Infection Market: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.